ALDR - Alder BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Alder BioPharmaceuticals, Inc.

11804 North Creek Parkway South
Bothell, WA 98011
United States
425-205-2900
http://www.alderbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees202

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert W. AzelbyPres, CEO & Director791.63kN/A1968
Mr. Carlos CampoyChief Financial Officer398.2kN/A1965
Ms. Erin M. LavelleChief Operating Officer955.12kN/A1978
Mr. James B. BucherExec. VP, Gen. Counsel & Corp. Sec.594.64kN/A1966
Mr. Randal A. HasslerExec. Sr. VP of Pharmaceutical OperationsN/AN/A1957
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Corporate Governance

Alder BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.